

Summit Corporation plc
(“Summit” or “the Company”)

ZEBRAFISH DATA SUPPORTS NEW DRUG CANDIDATE MOVING INTO HUMAN CLINICAL TRIALS

Data Form Part of a Successful Safety and Toxicity Filing to the UK’s Regulatory Agency MHRA

Oxford, UK, 8 August 2007 – Summit Corporation plc (AIM: SUMM), a leading UK biotechnology company, announces that, for the first time, data generated by its zebrafish technology platform about the safety and toxicity of potential drug candidates has formed part of a successful submission to the UK’s Medicines and Healthcare products Regulatory Agency (“MHRA”). This submission has permitted Summit’s client, an unnamed UK biotechnology company, to advance its candidate into Phase I human clinical trials.

Summit has built a world-leading capability in testing potential drug compounds using zebrafish. This capability is extremely valuable to drug development companies as it rapidly provides important whole organism data about the safety and toxicity of drug-like molecules and is predictive of effects that might be seen in humans. This technology has the potential to accelerate the discovery process and reduce overall costs relating to drug candidates that might otherwise fail as a result of safety or toxicity issues in later stages of development.

Summit’s market-leading zebrafish technology platform, which can also be used to generate models of human disease for target validation activities, has been used by seven of the world’s top ten pharmaceutical companies in the past 12 months.

Steven Lee, PhD, CEO of Summit said: “The use of our zebrafish safety and toxicity data as part of a regulatory safety submission is very significant and exciting for Summit. The acceptance of this submission by the MHRA demonstrates understanding of the data our zebrafish platform produces and a high level of confidence in this technology. Furthermore, the success of our client’s submission provides further validation of the value this technology brings to early stage drug discovery and as a Company we are confident this will continue to be recognised by the wider industry.”

- ends -

For more information please contact:

Summit plc

Steven Lee, PhD, Chief Executive Officer
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations

Tel: +44 (0)1235 443910

Citigate Dewe Rogerson

Mark Swallow / David Dible / Valerie Auffray

Tel: +44 (0)207 638 9571

Evolution Securities

Tim Worlledge / Bobbie Hilliam / Neil Elliot

Tel: +44 (0)207 071 4300

About Summit plc

Summit plc is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company's internal drug development programmes are underpinned by its advanced carbohydrate chemistry and drug screening (chemical genomics) technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.

Summit plc has a broad range of drug discovery programmes in the clinical, pre-clinical and discovery stages of development, which target serious diseases with a high unmet medical need. These therapeutic areas include neuro-disorders (neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases, oncology and regenerative medicines.

Summit plc's in-house drug development capabilities combine world-class expertise in both carbohydrate chemistry with high-volume, high-content screening using its proprietary zebrafish and fruitfly technologies (chemical genomics). These whole organism screens have the potential to dramatically decrease the time and cost of drug discovery and development by delivering data that are highly predictive of the efficacy and toxicity of potential drug compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October 2004 – symbol: SUMM

Further information about the company is available at www.summitplc.com

This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.